Moderna (MRNA) Announces Qatar Ministry of Public Health Issues Emergency Use Authorization for COVID-19 Vaccine
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Investors Poured More Money Into Stocks in Past 5 Months Than Last 12 Years, Says BofA, Analysts Worried About Stretched Valuations
- Amazon.com warehouse workers vote to reject forming union in Alabama
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Qatar Ministry of Public Health has issued an emergency use authorization for COVID-19 Vaccine Moderna.
“I want to thank the Qatar Ministry of Public Health for this authorization, which marks an important step forward in the global fight against COVID-19. We appreciate their continued confidence in our mRNA vaccine,” said Stéphane Bancel, Chief Executive Officer of Moderna.
The approval is based on the totality of scientific evidence shared by the Company, including a data analysis from the pivotal Phase 3 clinical study announced on November 30. Qatar has secured access to COVID-19 Vaccine Moderna through a supply agreement announced on October 26, 2020.
Moderna has also received authorization for its COVID-19 vaccine from health agencies in the United States, Canada, Israel, the European Union, the United Kingdom, Switzerland and Singapore. Moderna is also working with additional health agencies and with the World Health Organization on the authorization of its vaccine in respective jurisdictions.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- France's Top Health Body To Say An "M-RNA" Vaccine Should Be Used For Second Covid-19 Shot After First Injection With Astrazeneca - Reuters
- Genmab A/S (GMAB) and Seagen (SGEN) Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin BLA for Patients with Recurrent or Metastatic Cervical Cancer
- RedHill Biopharma's (RDHL) Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!